Remimazolam for Postoperative Atrial Fibrillation — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Remimazolam for Postoperative Atrial Fibrillation — Stella

Home/Coronary Artery Bypass Grafting/

View on ClinicalTrials.gov

Recruiting

Back to Coronary Artery Bypass Grafting trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

The Affiliated Hospital of Yangzhou University., Yangzhou, Jiangsu

Key details

Sponsor

Yangzhou University

Enrollment target

~50 participants

Started

February 2023

Primary completion

December 2026

Age range

50 Years – 70 Years

Last updated June 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.